GATAD2B: A Non-Coding RNA Molecule Regulating Gene Expression
GATAD2B: A Non-Coding RNA Molecule Regulating Gene Expression
GATAD2B, also known as Transcription repressor p66 beta component of the MeCP1 complex, is a non-coding RNA molecule that plays a critical role in gene regulation in cell signaling pathways. It is a key component of the MeCP1 complex, which is a protein complex involved in the regulation of gene expression. GATAD2B functions as a transcription repressor, which means it can prevent the activation of RNA polymerase II (RNA-II) and repress the gene transcription.
GATAD2B is a 24.8 kilobase (kb) protein and has a calculated molecular weight of 13.9 kd. It is composed of two major domains: a N-terminal alpha-helix domain and a C-terminal beta-sheet domain. The N-terminal domain has a single beta-strand and contains a putative RNA-binding domain (RBS) that is known to interact with the RNA-II machinery. The C-terminal domain has a beta-sheet structure and contains a conserved GAT domain, which is known to play a role in the regulation of gene expression.
GATAD2B is highly expressed in various tissues, including brain, heart, and muscle. It is also expressed in various cell types, including neurons, astrocytes, and macrophages. GATAD2B has been shown to play a role in the regulation of gene expression in various cellular processes, including cell signaling pathways, cell cycle regulation, and DNA replication.
One of the most interesting aspects of GATAD2B is its function as a transcription repressor. GATAD2B can interact with RNA-II machinery and prevent the activation of RNA-II. This interaction between GATAD2B and RNA-II machinery suggests that GATAD2B may be a potential drug target or biomarker for various diseases.
GATAD2B has been shown to play a role in the regulation of gene expression in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, GATAD2B has been shown to be downregulated in various cancer types, including breast cancer, lung cancer, and colon cancer. This suggests that targeting GATAD2B may be a potential strategy for cancer treatment.
In addition to its role in cancer, GATAD2B has also been shown to play a role in neurodegenerative diseases. GATAD2B has been shown to be involved in the regulation of gene expression in neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that targeting GATAD2B may be a potential strategy for the treatment of neurodegenerative diseases.
GATAD2B has also been shown to play a role in developmental disorders. For example, GATAD2B has been shown to be involved in the regulation of gene expression in Down syndrome, a genetic disorder that affects approximately 1 in 800 people. This suggests that targeting GATAD2B may be a potential strategy for the treatment of Down syndrome.
In conclusion, GATAD2B is a non-coding RNA molecule that plays a critical role in gene regulation in cell signaling pathways. Its function as a transcription repressor suggests that it may be a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of GATAD2B in disease progression and the development of effective therapies.
Protein Name: GATA Zinc Finger Domain Containing 2B
Functions: Transcriptional repressor (PubMed:12183469, PubMed:16415179). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). Enhances MBD2-mediated repression (PubMed:12183469, PubMed:16415179). Efficient repression requires the presence of GATAD2A (PubMed:16415179). Targets MBD3 to discrete loci in the nucleus (PubMed:11756549). May play a role in synapse development (PubMed:23644463)
The "GATAD2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GATAD2B comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GATB | GATC | GATD1 | GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF) | General transcription factor IIH | Geranylgeranyl transferase | Geranylgeranyl transferase type-1 | GET1
